Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab

BACKGROUND: Immune checkpoint inhibitors (ICIs) are increasingly being used for the treatment of upper gastrointestinal cancers [esophageal cancer and gastric cancer (GC)]. They cause imbalances in immunological tolerance, resulting in immune-related adverse events (irAEs). Although irAEs have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Yoshihiro, Baba, Yoshifumi, Toihata, Tasuku, Harada, Kazuto, Ogawa, Katsuhiro, Iwatsuki, Masaaki, Iwagami, Shiro, Miyamoto, Yuji, Yoshida, Naoya, Baba, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830324/
https://www.ncbi.nlm.nih.gov/pubmed/36636073
http://dx.doi.org/10.21037/jgo-22-281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830324/
https://www.ncbi.nlm.nih.gov/pubmed/36636073
http://dx.doi.org/10.21037/jgo-22-281

Ejemplares similares